Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 15/20 | 0.46 |
| ▸ | CRHR1 | P34998 | 3/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.45 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.42 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.42 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5133381 | 0.79 | AR (0.49) | S1PR1CRHR1AR | |
| SCHEMBL6469271 | 0.75 | SIRT6 (0.41) | CRHR1HCAR3 | |
| SCHEMBL2770688 | 0.74 | S1PR1 (0.62) | S1PR1S1PR3S1PR5 | |
| SCHEMBL15372625 | 0.71 | S1PR1 (0.62) | S1PR1S1PR3S1PR5 | |
| SCHEMBL5042470 | 0.71 | HCAR3 (0.46) | ARHCAR3 | |
| SCHEMBL7519109 | 0.70 | CRHR1 (0.71) | S1PR1CRHR1 | |
| SCHEMBL30482977 | 0.69 | SIRT6 (0.46) | HCAR3 | |
| SCHEMBL5133491 | 0.69 | HCAR3 (0.43) | ARHCAR3 | |
| SCHEMBL2833446 | 0.68 | CRHR1 (0.43) | S1PR1CRHR1S1PR3S1PR5HCAR3 | |
| SCHEMBL3031151 | 0.68 | S1PR1 (0.61) | S1PR1S1PR3S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1654260-A4 | 6-MENBERED HETEROARYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PROD INC (US) | 2008-09-24 | — | — | EP | claimed |
| EP-1654260-A2 | 6-MENBERED HETEROARYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2006-05-10 | — | — | EP | claimed |
| WO-2005011601-A2 | 6-MENBERED HETEROARYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS, INC. (US) | 2005-02-10 | — | — | WO | claimed |
| US-20050107381-A1 | 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders | PFIZER, INC. | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107381-A1 | 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders | APP, BACE1, SNCA | S1PR1 2060/4885CRHR1 1005/4885AR 2835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.